Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

AnteoTech Temettü

Temettü kriter kontrolleri 0/6

AnteoTech şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.1%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-AU$0.0036
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ADO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ADO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

AnteoTech Piyasaya Karşı Temettü Getirisi

ADO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ADO)	n/a
Pazarın Alt %25'i (AU)	2.6%
Pazarın En İyi %25'i (AU)	6.0%
Sektör Ortalaması (Chemicals)	2.1%
Analist tahmini (ADO) (3 yıla kadar)	n/a

Önemli Temettü: ADO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ADO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ADO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ADO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

AnteoTech Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

AnteoTech Limited, Annual General Meeting, Nov 26, 2024

New major risk - Financial position

Full year 2024 earnings released: AU$0.004 loss per share (vs AU$0.006 loss in FY 2023)

AnteoTech Limited to Report Fiscal Year 2024 Results on Aug 28, 2024

New minor risk - Share price stability

AnteoTech Limited, Annual General Meeting, May 28, 2024

AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 5.4 million.

AnteoTech Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

We're Keeping An Eye On AnteoTech's (ASX:ADO) Cash Burn Rate

AnteoTech Limited to Report First Half, 2024 Results on Feb 28, 2024

AnteoTech Limited, Annual General Meeting, Nov 14, 2023

AnteoTech Limited, Annual General Meeting, Nov 14, 2023

Full year 2023 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Anteotech Limited Announces Appointment of Mr. Andrew Cook as Chief Financial Officer

AnteoTech Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

New major risk - Share price stability

AnteoTech Limited Announces Retirement of Christopher Parker from the Board of Directors

Will AnteoTech (ASX:ADO) Spend Its Cash Wisely?

Board Member exercised options to buy AU$70k worth of stock.

First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2022)

AnteoTech Limited Appoints Tsui Min Lian as Chief Marketing Officer, Effective 15 March 2023

Non-Executive Director recently sold AU$61k worth of stock

Is AnteoTech (ASX:ADO) In A Good Position To Invest In Growth?

High number of new and inexperienced directors

AnteoTech Ltd Announces Halt of European Rat Clinical Trial to Refocus Initiatives

AnteoTech Limited Appoint Executives

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.003 loss in FY 2021)

AnteoTech Limited, Annual General Meeting, Nov 17, 2022

Companies Like AnteoTech (ASX:ADO) Are In A Position To Invest In Growth

AnteoTech Limited Appoints David Radford as Managing Director, Effective from 4 October 2022

AnteoTech Limited SHS to Be Deleted from OTC Equity

Non-Executive Director recently sold AU$106k worth of stock

AnteoTech Ltd Announces Updated COVID-19 RAT Receives Regulatory Approval in Europe

Non-Executive Director recently sold AU$220k worth of stock

High number of new and inexperienced directors

AnteoTech Limited Announces Executive Changes

Companies Like AnteoTech (ASX:ADO) Are In A Position To Invest In Growth

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

AnteoTech Limited Provides Update on Its Therapeutic Goods Administration Submission

AnteoTech Limited Provides Update on Its Therapeutic Goods Administration Submission

Non-Executive Director recently sold AU$108k worth of stock

Company Secretary Duncan Cornish has left the company

High number of new and inexperienced directors

We Think AnteoTech (ASX:ADO) Can Easily Afford To Drive Business Growth

High number of new and inexperienced directors

Independent Non-Executive Director recently bought AU$59k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.002 loss in FY 2020)

Chief Financial Officer Gail Jukes has left the company

Non-Executive Director recently sold AU$112k worth of stock

AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 12.000001 million.

AnteoTech Limited announced that it expects to receive AUD 12.000001 million in funding

We Think AnteoTech (ASX:ADO) Can Easily Afford To Drive Business Growth

Independent Non-Executive Director has left the company

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2020)

New 90-day high: AU$0.21

AnteoTech Customer Ellume Secures Us Contract

We're Not Very Worried About AnteoTech's (ASX:ADO) Cash Burn Rate

AnteoTech Progresses COVID-19 Test Toward Market Launch

AnteoTech Ltd Freeze Design of COVID-19 Antigen Rapid Test After Showing Saliva Proxy Sample Use Case Effectiveness

Independent Non-Executive Director exercised options to buy AU$208k worth of stock.

Full year earnings released - AU$0.002 loss per share

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin